Résultats de la recherche - Michael K. Gibson
- Résultat(s) 1 - 20 résultats de 27
- Aller à la page suivante
-
1
-
2
-
3
-
4
Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes par Roberto Gomez-Casal, Chitralekha Bhattacharya, Nandita Ganesh, Lisa A. Bailey, Per Basse, Michael K. Gibson, Michael W. Epperly, Vera Levina
Publié 2013Artigo -
5
Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck par Min Yao, Nicholas Galanopoulos, Pierre Lavertu, Pingfu Fu, Michael K. Gibson, Athanassios Argiris, Rod Rezaee, Chad Zender, Jay Wasman, Mitchell Machtay, P. Savvides
Publié 2014Artigo -
6
Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer par Brian A. Boone, Jennifer Steve, Alyssa M. Krasinskas, Amer H. Zureikat, Barry C. Lembersky, Michael K. Gibson, Ronald G. Stoller, Herbert J. Zeh, Nathan Bahary
Publié 2013Artigo -
7
Esophagectomy for T1 Esophageal Cancer: Outcomes in 100 Patients and Implications for Endoscopic Therapy par Arjun Pennathur, Andrew Farkas, Alyssa M. Krasinskas, Peter F. Ferson, William E. Gooding, Michael K. Gibson, Matthew J. Schuchert, Rodney J. Landreneau, James D. Luketich
Publié 2009Artigo -
8
The Impact of Tumor Volume and Radiotherapy Dose on Outcome in Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and Neck Treated With Stereotactic Body Radiation... par Jean-Claude M. Rwigema, Dwight E. Heron, Robert L. Ferris, Regiane S. Andrade, Michael K. Gibson, Yong Yang, Cihat Ozhasoglu, Athanassios Argiris, Jennifer R. Grandis, Steven A. Burton
Publié 2010Artigo -
9
Response assessment by combined PET–CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy par Vida Almario Passero, Barton F. Branstetter, Y. Shuai, Dwight E. Heron, Michael K. Gibson, Stephen Y. Lai, S. W. Kim, Jennifer R. Grandis, Robert L. Ferris, Jonas T. Johnson, Athanassios Argiris
Publié 2010Artigo -
10
Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer par Harry H. Yoon, Zhaohui Jin, Oudom Kour, Lionel Aurelien Kankeu Fonkoua, Kohei Shitara, Michael K. Gibson, Larry J. Prokop, Markus Moehler, Yoon‐Koo Kang, Qian Shi, Jaffer A. Ajani
Publié 2022Revisão -
11
The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. par Xin Wei Wang, Wim Vermeulen, Jill D. Coursen, Michael K. Gibson, Shawn E. Lupold, Kathleen Forrester, Guangwen Xu, Lynne W. Elmore, Heidi Yeh, Jan H.J. Hoeijmakers, C C Harris
Publié 1996Artigo -
12
Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma par J.L. Geiger, Julie E. Bauman, Michael K. Gibson, William E. Gooding, Prakash Varadarajan, Athanasios Κotsakis, Daniel Martı́n, J. Silvio Gutkind, Matthew L. Hedberg, Jennifer R. Grandis, Athanassios Argiris
Publié 2016Artigo -
13
Remote monitoring titration clinic to implement guideline-directed therapy for heart failure patients with reduced ejection fraction: a pilot quality-improvement intervention par Erick Romero, Stella Yala, Camryn Sellers-Porter, Genevieve Lynch, Veronicah Mwathi, Yvette Hellier, Svetlana Goldman, Paulo Rocha, Jeffrey Fine, David Liem, Julie T. Bidwell, Imo Ebong, Michael K. Gibson, Martín Cadeiras
Publié 2023Artigo -
14
Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck par Athanassios Argiris, Athanasios Κotsakis, Tien Hoang, Francis P. Worden, P. Savvides, Michael K. Gibson, Rekha Gyanchandani, George R. Blumenschein, H.X. Chen, Jennifer R. Grandis, Paul M. Harari, M.S. Kies, S. Kim
Publié 2012Artigo -
15
Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Nec... par Athanassios Argiris, Dwight E. Heron, Ryan P. Smith, Seungwon Kim, Michael K. Gibson, Stephen Y. Lai, Barton F. Branstetter, Donna M. Posluszny, Lin Wang, Raja R. Seethala, Sanja Đačić, William E. Gooding, Jennifer R. Grandis, Jonas T. Johnson, Robert L. Ferris
Publié 2010Artigo -
16
Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer par Aleksandar Z. Obradovic, Diana Graves, Michael Korrer, Yu Wang, Sohini Roy, Abdullah Naveed, Yaomin Xu, Adam Luginbuhl, Joseph Curry, Michael K. Gibson, Kamran Idrees, Paula J. Hurley, Peng Jiang, X. Shirley Liu, Ravindra Uppaluri, Charles G. Drake, Andrea Califano, Young J. Kim
Publié 2022Artigo -
17
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study par Joshua Bauml, Tanguy Y. Seiwert, David G. Pfister, Francis P. Worden, Stephen V. Liu, Jill Gilbert, Nabil F. Saba, Jared Weiss, Lori J. Wirth, Ammar Sukari, Hyunseok Kang, Michael K. Gibson, Erminia Massarelli, Steven Powell, Amy Meister, Xinxin Shu, Jonathan D. Cheng, Robert I. Haddad
Publié 2017Artigo -
18
Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer par Athanassios Argiris, Julie E. Bauman, James Ohr, William E. Gooding, Dwight E. Heron, Umamaheswar Duvvuri, Gregory J. Kubicek, Donna M. Posluszny, Maria Vassilakopoulou, S. Kim, Jennifer R. Grandis, Jonas T. Johnson, Michael K. Gibson, D.A. Clump, John T. Flaherty, Simion I. Chiosea, Barton F. Branstetter, Robert L. Ferris
Publié 2016Artigo -
19
Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours par Aung Naing, Todd M. Bauer, K. Papadopoulos, Osama E. Rahma, Frank Tsai, Elena Garralda, Jarushka Naidoo, Sachin Gopalkrishna Pai, Michael K. Gibson, Igor I. Rybkin, Dee Dee Wang, David F. McDermott, Angelica Fasolo, Maria J. de Miguel, M. Shaheen, Yonchu Jenkins, Howard Kallender, Sven Gogov, Emil Kuriakose, Michael J. Pishvaian
Publié 2019Artigo -
20
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck par Robert L. Ferris, Nabil F. Saba, Barbara J. Gitlitz, Robert I. Haddad, Ammar Sukari, Prakash Neupane, John C. Morris, Krzysztof Misiukiewicz, Julie E. Bauman, Moon J. Fenton, Antonio Jimeno, Douglas R. Adkins, Charles Schneider, Assuntina G. Sacco, Keisuke Shirai, Daniel W. Bowles, Michael K. Gibson, T. Nwizu, Raphaël Gottardo, Kristi L. Manjarrez, Gregory N. Dietsch, James Kyle Bryan, Robert M. Hershberg, Ezra E.W. Cohen
Publié 2018Artigo
Outils de recherche:
Sujets similaires
Medicine
Internal medicine
Cancer
Oncology
Head and neck cancer
Head and neck squamous-cell carcinoma
Immunotherapy
Radiation therapy
Chemotherapy
Surgery
Colorectal cancer
Biology
Breast cancer
Cetuximab
Nivolumab
Adenocarcinoma
Biochemistry
Gene
Pembrolizumab
Regimen
Adverse effect
Bevacizumab
Cell biology
Chemoradiotherapy
Cisplatin
Esophageal cancer
Esophagectomy
Esophagus
Gastroenterology
Genetics